| Project/Area Number |
22591145
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Kurume University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MATSUISHI Toyojiro 久留米大学, 医学部, 教授 (60157237)
KAWAHARA Yukie 久留米大学, 医学部, 講師 (10279135)
MIFUNE Hiroharu 久留米大学, 医学部, 准教授 (70174117)
TANAKA Eiichiro 久留米大学, 医学部, 教授 (80188284)
YAMASHITA Yusihro 久留米大学, 医学部, 准教授 (90211630)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
KOJIMA Masayasu 久留米大学, 医学部, 教授 (20202062)
TAKAHASHI Tomoyuki 久留米大学, 医学部, 准教授 (20332687)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2012: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2010: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 発達小児科学 / Rett 症候群 / グレリン / 神経内分泌調節 / レット症候群 / 発達障害 / 神経内分泌ホルモン / 摂食障害 / 臨床応用 / デカノイルグレリン / 脳発達 / 神経内分泌 / ペプチドホルモン / 遺伝子解析 / 脳神経科学 / Translational Research / 生理活性 / 脳神経疾患 / トランスレーショナルリサーチ |
|---|
| Research Abstract |
In this study, we investigated the dynamics of ghrelin production in patients with Rett syndrome (RTT) together with that in mecp2-null mouse model of RTT (RTT-mouse). We also examined the effectiveness of “ghrelin-injection” on several clinical symptoms of RTT by using this RTT-mouse. Plasma levels of ghrelin were significantly lower in RTT patients with eating disorder or patients with insufficiency in gastro-intestinal movement. Deregulation of ghrelin production was also noted in the RTT-mouse. Daily injection of ghrelin into the RTT-mouse ameliorated the clinical symptom of them including “tremor”, “gait disturbance”, “hindlimb clasping” and “malnutrition” (body weight loss) from 6-9 weeks age. These findings of us support the future implication of “ghrelin-treatment” against several clinical symptoms typically seen in RTT patients.
|
